Medtronic Stock Price, News & Analysis

Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the third quarter of fiscal year 2025. The dividend will be payable on January 10, 2025, to shareholders of record as of December 27, 2024. This declaration aligns with the dividend increase announced in May 2024.

As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.

Medtronic addresses the environmental impact of healthcare technology, highlighting that the healthcare sector contributes to 4.6% of global greenhouse gas emissions. The company emphasizes three key approaches to sustainable healthcare: recognizing development timelines, reimagining products and packaging, and recruiting partners. Medtronic has installed 22 solar arrays across 16 locations, generating over 35 MWs of power, and signed a virtual power purchase agreement to cover nearly all U.S. energy needs. The company is focusing on sustainable product design through its Sustainability Development Center and emphasizes the importance of supply chain collaboration, as Scope 3 emissions account for over 90% of their carbon footprint.

Medtronic has released its fiscal year 2024 Impact Report, highlighting achievements in healthcare equity and environmental sustainability. The report features the success of the Healthy Neighbor program, showing 71% of enrolled patients with high blood pressure and 63% with uncontrolled diabetes achieved meaningful progress. The company reached 51% women in its global workforce and reduced emissions intensity by 52% compared to FY20. Key accomplishments include investing $2.7 billion in R&D, improving healthcare access for over 78 million patients, and meeting 42% of operational energy needs with renewables. The company is on track for several sustainability goals, including sourcing 50% of energy from renewable sources by FY25.

Medtronic (NYSE: MDT) has received FDA clearance for its new InPen™ app with missed meal dose detection, enabling the launch of its Smart MDI system with Simplera™ CGM. The system combines a smart insulin pen with a new disposable CGM that's 50% smaller than previous versions. This marks the first system to provide real-time, personalized recommendations for missed or inaccurate insulin doses. The technology addresses a critical need, as patients typically miss 1 in 3 insulin doses. The company plans a phased rollout, starting with existing CGM and InPen™ customers before a broader commercial launch.

Medtronic (MDT) reported strong Q2 FY25 results with revenue of $8.4 billion, up 5.3% as reported and 5.0% organic. GAAP EPS was $0.99, while non-GAAP EPS reached $1.26. The company raised its FY25 guidance, now expecting organic revenue growth of 4.75-5% and non-GAAP EPS of $5.44-$5.50.

Growth was driven by innovation across key franchises including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation. The Cardiovascular portfolio grew 6.1%, Neuroscience increased 7.1%, Medical Surgical rose 1.2%, and Diabetes jumped 12.4%. Strong performance in international markets and continued adoption of new products contributed to the positive results.

Medtronic (NYSE:MDT) has announced it will release its second quarter fiscal year 2025 financial results on Tuesday, November 19, 2024, at approximately 5:45 a.m. CST. The company will host a video webcast at 7:00 a.m. CST to discuss the results. The fiscal quarter ended on October 25, 2024. Future earnings releases are scheduled for February 18, 2025 (Q3) and May 21, 2025 (Q4). Medtronic, headquartered in Galway, Ireland, operates across 150+ countries with 95,000+ employees, providing technologies and therapies that treat 70 health conditions.

Medtronic (NYSE: MDT) announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for its Symplicity Spyral™ renal denervation catheter, effective January 1, 2025, for up to three years. The TPT approval aims to improve patient access to this breakthrough treatment for uncontrolled high blood pressure by reducing cost barriers for healthcare systems. The device, FDA-approved in November 2023, is a minimally invasive procedure that uses radiofrequency energy to calm overactive kidney nerves contributing to high blood pressure. The system is currently approved in over 75 countries and has been used to treat more than 25,000 patients globally.

Medtronic (NYSE: MDT) announced new two-year data from its SPYRAL HTN-ON MED clinical trial showing significant blood pressure reductions using the Symplicity™ Spyral renal denervation (RDN) system. The study demonstrated superior results compared to sham patients, with RDN group showing -12.1 mmHg reduction in 24-hr ABPM versus -7.0 mmHg in sham group. The company also announced plans for the SPYRAL GEMINI clinical trial to study multi-organ denervation, and the expansion of the GSR-DEFINE clinical trial to U.S. sites. The Symplicity Spyral system is currently approved in over 75 countries.

Medtronic (NYSE: MDT) has received FDA approval for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter, making it the first company with two pulsed field ablation (PFA) technologies for atrial fibrillation treatment. The system combines high-density mapping with dual energy (pulsed field and radiofrequency) ablation capabilities for treating persistent atrial fibrillation and atrial flutter. The Sphere-9 catheter features a 9mm lattice tip and enables physician treatment flexibility with its wide area focal design. The approval follows successful results from the SPHERE Per-AF study and previous CE Mark and Australian approvals.